Comparative Pharmacology
Head-to-head clinical analysis: ULORIC versus ZYLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULORIC versus ZYLOPRIM.
ULORIC vs ZYLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.
100-300 mg orally once daily, maximum 800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 5-8 hours. This short half-life supports once-daily dosing for maintenance of therapeutic urate-lowering effect.
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (prolonged to 48-72 hours in renal impairment). Clinical context: oxypurinol half-life determines dosing interval; dose adjustment required for CrCl < 20 mL/min.
Renal excretion of unchanged drug accounts for approximately 40-45% of the dose. Biliary/fecal excretion eliminates about 50-55% of the dose, primarily as oxidative metabolites.
Renal: allopurinol ~10% unchanged, oxypurinol ~70% unchanged; total renal elimination ~76% (allopurinol + oxypurinol); fecal/biliary: minor (~12-20% as allopurinol, ~3-5% as oxypurinol).
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor